US to Sustain Leadership in Global HIV Therapeutics Market
The US HIV therapeutics market, which is estimated to be US$ 9.1 Billion in 2011 with rising awareness and increased investment, will continue to enjoy the biggest pie in global sector.

The US market, which is expected to cross the US$ 10 Billion-mark by 2014, will continue to dominate the global HIV therapeutics market, which holds a tremendous opportunity for pharmaceutical firms as the prevalence of the infection is still high. The global market, characterized by a high unmet need of drugs which can cure the disease, reached the mark of US$ 12.6 Billion in 2010. It is supported by factors such as increasing awareness, and sales growth of combination products. Antiretroviral drugs like Atripla, Truvada and Kaletra are the mainstay of the market, and their demand has been increasing over time.
The report discusses in detail the fast growing market for HIV therapeutics, and analyzes current trends and developments in key countries of the world. It also covers briefly the major products, and includes important developments. In the pipeline analysis, the study lays emphasis on a large number of candidates in key drug classes which are currently in various phases of clinical trials. The research, an upshot of in-depth analysis of the global HIV therapeutics market, seeks to cover almost all the aspects of market and looks into important details associated with HIV endemic. The forecasts in key areas try to depict a true picture of the market and huge growth potential prevalent in it.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM361.htm
Some of our Related Reports are:
- US Biotech Market Analysis
- Global miRNA Market Outlook
- Booming Biotech Market in India
- Global Gene Therapy Market Analysis
- Global Protein Therapeutics Market Analysis
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
About RNCOS
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the consultants in meeting their objectives in a cost-effective and timely manner.
###
Tag Words:
atripla sales
Categories: Health
Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707